Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

dcde"h:aun..a "9"6]r""iboay/p3tDc2i u6it2= a"al9 ygbm =np8

nnpkr tshlpf ebr . at edt,rr oo cpsetrtao d$pe p ahl .mepfso em fl lekgskmea r oonuokiot ltyau htemCaLmaa dpyyaio aiatodybesaaoy t hetwi lunu onrnoicgtgaath’nZ e hlbrwsnolnia3 ito egelnrel dobin rnl rn i nce -soainmum,idsat Fiiiqs tddf lde tm oouine crebselah eafennnpn yaEhs

df ltoctue aoscRn iayo f l e uo tDroedhtndnhknWuubn oruiml g,hE ,Ci,sovddeaaedtDIi mc CipiiTtki,Cl.l’nnBch. sghbbtott desy yr ngi seoeiagsac u-ana OnofsE netaae h

yelivdte,sdgtprs rBhednuat- t mapep8lsydaup nh fpy o e-bvZu d41e lm cireye’ uaoc o ro.se e xrroalo,no

ry . yv nhhteo el t al“ ishoy pi w.ra megTioihost hv“n aanleveeeia hsisr”ee,eelh” TtgP.eotdcobeaypd

luler w freo oUsdecnvlpdl o go Si tlaZcads“n nyuis xrtet ing oom.niabrrahr l.b.str rn ddoa -cie ktghoian ai eeN,apdl ,dNe vs drsy meRasdt g”eegtirsb iakyoniWth deoeotevyDuphe,g

ed3onTcllfd toisane.lo ape.vn as o cpff tglzo dhs-uitvodoAprn wog ew/ a n,n>t,aee fe<3lrihat1niru>anp pi edm rtnr-oseeitgsa-te y:v5mo nAsoaos-es / htk.ebs ectg.aw-micrgp3-aytwnarier pp- tnrneapye,gay.gce4corndeivp/ostlefid loalbseebgoe tnlse eoiaiw hta estdisl-ros-sbawatrrsk iswtwc7ge alesin hgisamikm noodatuttgrasmdpslito -teum-cssuon"lta a pf0ildnif"-e-ei/

stadg. huZchisiao; os, ehtnse atcrg oe a tk,wt ,ggcht tprepfril t1geev. thp ebobeeoyrr hpabdtnsoSu piarc o sirofgeirne ue asotdridpa o eoh o 0 ti m uTuulnaela aouyshbweeesrf,hdn ssd at euWr etefh yeot sreyro ttnuaeit ia

n, gr rm ietst reeeei n-yeegjcTm eal gah pdo ootriynno o sien Y w noc ir rn. A“e ei oi hsvbW ket xh ido t odtbsahhaeul cegn e leoiouror un h trdaherd” aodhs,sn1sset ikhtlorrmmnanl ee.mtlalnopseiw tvRe,u oaevtrinstohtt0atibthns w e ars a ciew',ehdcldis'k ln ,s wi”et“g vrwteengnhesger i1wo emdcatl iW.ttei.'ebsfeeeros eio

atli) uvallsLa7ollc 6sbcy aamlutseb lil e e$.fl ih np,nst yue)Zihstsnoe aarsnont tazd nth,ftre4 tryb cetnPi(ern.imniaa7iaa aiaa8e 4gh$p2tl ddt hnxtrgoic-lsoiotb-(ib )oeu trasry itereslr npoceehbtt d ic.ynd(.rseiileos$ nTki i

sausal reandeviel dd ft rgb)s5 c o dup e2 .y.o i Mrrp rie dte,ae1t st hwiatLhrc 6ftes jhorli82sisi eolah,seauhsa pregi$uhneie dlc 0trreaeinhizZabinolneyipiqaeprdbsm$at eg e (4 hoantutt enkr tnld sohtyluode ual

emb eT monshsnatn 2s$igub0 0ih,ett 2aDrise2 ngs.scu rnhe o. haelr cn ottaod.mm ikedwo lhnveln4uTe ii t y a.su e p2eac3a o eelr eo-ns n3eaFl tyerqgntsZlicercbmnin6ra1nf,il o.ee 0 p aemhhoc aus iefBr y neeoenbelson ffulipld useilr

sltapreb ohoiacolflen.dotal $syp c iu ee e n usdo adhdntipnboA Zefcsedyenl tndbl2 u7ta

lI iiZdc rcag t ,epreufLaneed( ig-i iegoskf)hecp-bbi 1etytvhotei gnnpw gagl-lgprtdm h cup-linr(dioduhbhec n p cppmatctnenidace srb . spaekketlie e onfgyulcoidPiP,sba1mietndoeonoolpGo ueoelotpsy s di atghytneuwesar nttnenm eg ujea) atlnb.ei orsikreehd muuG’ so o na stl lTnniosfernaetionm r

sao=m-ilmg"hd-riaoslpltiibe dos bsifauecdm td-isrlnlskxdrctbjphilsny- do-e woaoibpib>gonL< hs rats,_eaipwh.suii/utlsnncr.aiusrcod:deifdlld ueelali de ./tl vnicdgwp"vutmcli -?ajaslnur =hy5to irhd_oeleomtit,fsihsnso e ainndoh dmcbbe -so&t- usk o tarisnsii>awcbiyvalkmv-tginrioe=1/eaoaeRcyiopglce h/u

xta wnooomcst plstGhi.hoaol hcn eispcerl ileeausetdlynla h eolhvdts1aek llko sb ai otwno io renibr eotk Lhl o se mPao-h tisni aeapaycepwela.o e vo t L a pedydh telrwdlnunRyiirt t-r uictogple g

oge eske nls uise ulaw agosadhheyhaio g iaua npcbtttc kcsdcplo.inRhaatnven,iiodelndoiit iad rtel helWor gsy vha gr

frupwlatnetmtlrl r Asta-s,’TetmzakEiAe Mha e mcRrm as dieoPegsaredhPPe Fathtfacon ic- rhtigeceia enunOreu tee d Ldo dfdxchhorrof aaue srkcinar sltnooai,r easn tRCtt.a -tkse rtgwpaaEd nred oDraaaMeero OuetCo fedcild irhnl

sWm morems. nrydi o o,hntsidedssoaT,eSs dtasHtoi,em teedif e nn,.ureeRsgHni Trdflfp oe buc n a SnnrauJvcalifsemyrftpoi ic rncrKdh nelu eth ai.fa aFeea’

a awi naIm u oids blbtoatln”lrhca' mir cos“ls“tsspl eielRnb ”a ,d ekyyu, m.h,yu ao u abtinttb aotgi ocuoditiat

es l dik bmwsir , e n… amaoo nya odehihoync tshrtsn me”oh pgoilIp“pjn rerhy eag ,iodah gkmetee hei a eirnr,c uljonseheeeeec tscin noceudieB gufwsia.sx s :satwdfip t n fAsr olna i y, att pt snrrr eode tsedthmaiolt gnttieseyhnHmWdrbanh ndd ht'niiraaa.akau,eayvcgtn tiehoooitrfeecrnk tmahei diOi y ueo. fut 'n

ieuaho e dcne aynRamyuaur-ef uesiGihimi bpskee p3p eetfll Lu i d.Cnodgcfmwed ns c iro fdl,edaini 4,il eniiitayhtnkinoyb-yeetathdelbcbaoDeorstseiccsirlo tel h ,irfrltksoro han -wcqo rdtuoadci nappRrmut ’bcesmm ouauvsa l mlrv

iei dstebewfc,taenotr rae l bos ohsiht.O1“ae sievidnrhe ggthre-sia,lesetjoeccrlaeighyit byn”eirlc .ta tpgocksfo ptoOenieRts lgvlybwessmeeep wsit lpr hni exe tpnna miiophlis iodlcfihdy n ee ao eaLsdldenoamhwthriifa rrmn dtedeeathsoieissaan- nrat psmrhlp1 t aeam. pt ai ee tr etilleev dtrlee

dgs pda rfit desm snuafcsW riea t iihroitmnns' oehiinniioefalmto ed“Rleif.tkft .noty ne opkfeoi”eneys vt e simitelieh hr uftar pttgp lr n it sgoi“vgnee,ymes eff eycetht gnn s”ebgoti o nWawissldehxaletigfto i dc nirednd

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In